Results 41 to 50 of about 339,213 (296)
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
Pharmaceuticals, 2021 In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain +8 more
doaj +1 more source
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Biomedicines, 2016 Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy.
Adam Parslow +4 more
openaire +5 more sources
Site-selective protein modification via disulfide rebridging for fast tetrazine/trans-cyclooctene bioconjugation [PDF]
, 2020 An inverse electron demand Diels–Alder reaction between tetrazine and trans-cyclooctene (TCO) holds great promise for protein modification and manipulation.
Chudasama, V. +6 more
core +1 more source
Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
Scientific Reports, 2021 Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi +4 more
doaj +1 more source
HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
BIO Integration, 2023 Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang +9 more
doaj +1 more source
, 2023 Antibody drug conjugates (ADCs) continue to change the treatment paradigm of breast cancer and recent regulatory approvals of next generation ADCs are shifting how breast cancer is classified and treated. ADCs combine precision targeting with traditional cytotoxic treatment allowing for the delivery of highly potent chemotherapeutic agents to malignant
Farah, Raheem,, Vishal, Shah,
openaire +2 more sources
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
Clinical Medicine Insights: Oncology, 2012 Hodgkins lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb ...
Michelle Furtado, Simon Rule
doaj +1 more source
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
SLAS discovery : advancing life sciences R & D, 2020 The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody–drug conjugates (ADCs), in which biologically active drugs are coupled through chemical ...
Laurence Gauzy-Lazo +2 more
semanticscholar +1 more source
Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
Chemical and pharmaceutical bulletin, 2020 Auristatins are important payloads used in antibody drug conjugates (ADCs), and the most well-known compound family member, monomethyl auristatin (MMAE), is used in two Food and Drug Administration (FDA)-approved ADCs, Adcetris® and Polivy®.
Michinori Akaiwa +2 more
semanticscholar +1 more source
Strain prioritization and genome mining for enediyne natural products [PDF]
, 2016 The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine, and yet only 11 enediynes have been structurally characterized to date.
Ben Shen +18 more
core +2 more sources